The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients

Drug and Alcohol Dependence

Volumn 139, Issue , 2014, Pages 79-85

  Edelman, E Jennifer ^a,b   Chantarat, Tongtan ^c   Caffrey, Sarah ^a   Chaudhry, Amina ^d   O'Connor, Patrick G ^a   Weiss, Linda ^c   Fiellin, David A ^a,b   Fiellin, Lynn E ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

^d Chase Brexton Health Services   (United States)

Author keywords

Buprenorphine; HIV; Opioid related disorders; Risk behaviors

Indexed keywords

AMPHETAMINE; BUPRENORPHINE PLUS NALOXONE; CANNABIS; COCAINE; DIAMORPHINE; VIRUS RNA; BUPRENORPHINE; NALOXONE; NARCOTIC ANTAGONIST;

ADULT; AGE DISTRIBUTION; ARTICLE; BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; BISEXUALITY; CONDOM USE; CONTROLLED STUDY; DRUG ABUSE PATTERN; DRUG EFFICACY; FEMALE; HOMELESSNESS; HOMOSEXUAL FEMALE; HOMOSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MIDDLE AGED; OPIATE ADDICTION; PRIORITY JOURNAL; SELF REPORT; SEXUALITY; TREATMENT RESPONSE; VIRUS LOAD; COMPLICATION; DRUG ABUSE; HIGH RISK BEHAVIOR; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; UNSAFE SEX;

CANNABIS SATIVA; HUMAN IMMUNODEFICIENCY VIRUS 1;

BUPRENORPHINE; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NEEDLE SHARING; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RISK-TAKING; UNSAFE SEX;

EID: 84899961977     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.03.006     Document Type: Article

References (52)

1. Altice F.L., Bruce R.D., Lucas G.M., Lum P.J., Korthuis P.T., Flanigan T.P., Cunningham C.O., Sullifan L.E., Vergara-Rodriguea P.m., Fiellin D.A., Cajina A., Botsko M., Nandi V., Gourevitch M.N., Finkelstein R. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J. Acquir. Immune Defic. Syndr. 2011, 56(Suppl. 1):S22-S32. for the BHIVES Collaborative.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Publishing, Arlington, VA.
3. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955, 11:375-386.
4. Baron R.M., Kenny D.A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol. 1986, 51:1173-1182.
5. Bernaards C.A., Bellin T.R., Schafer J.L. Robustness of a multivariate normal approximation for imputation of incomplete binary data. Stat. Med. 2007, 26:1368-1382.
6. Bouhnik A.D., Carrieri M.P., Rey D., Spire B., Gastaut J.A., Gallais H., Obadia Y. Drug injection cessation among HIV-infected injecting drug users. Addict. Behav. 2004, 29:1189-1197. MANIF 2000 Study Group.
7. Braithwaite R.S., McGinnis K.A., Conigliaro J., Maisto S.A, Crystal S., Dayn N., Cook R.L., Gordon a., Bridges M.W., Seiler J.F., Justice A.C. A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care. Alcohol. Clin. Exp. Res. 2005, 29:1190-1197.
8. Bursac Z., Gauss C.H., Williams D.K., Hosmer D.W. Purposeful selection of variables in logistic regression. Source Code Biol. Med. 2008, 3:17.
9. Calsyn D.A., Crits-Christoph P., Hatch-Maillette M.A., Doyle S.R., Song Y.S., Coyer S., Pelta S. Reducing sex under the influence of drugs or alcohol for patients in substance abuse treatment. Addiction 2010, 105:100-108.
10. Calsyn D.A., Hatch-Maillette M., Tross S., Doyle S.R., Crits-Christoph P., Song Y.S., Harrer J.M., Lalos G., Berns S.B. Motivational and skills training HIV/sexually transmitted infection sexual risk reduction groups for men. J. Subst. Abuse Treat. 2009, 37:138-150.
11. Center for Strategic and Internationa Studies (CSIS) Task Force on HIV/AIDS. Combating the Twin Epidemics of the HIV/AIDS and Drug Addiction: Opportunities for Progress and Gaps in Scale 2008, CSIS, Washington, DC.
12. Center for Substance Abuse Treatment Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Imprvement Protocol (TIP) Series 40 2004, Susbstance Abuse and Mental Health Service Administration, Rockville, MD.
13. Chaudhry A.A., Botsko M. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J. Acquir. Immune Defic. Syndr. 2011, 56(Suppl. 1):S14-S21.
14. Cochran W.G. Some methods for strengthening the common χ2 tests. Biometrics 1954, 10:417-451.
15. Copenhaver M.M., Lee I.C., Baldwin P. A randomized controlled trial of the Community-friendly Health Recovery Program (CHRP) among high-risk drug users in treatment. AIDS Behav. 2013, 17:2902-2913.
16. Crawford N.D., Vlahov D. Progress in HIV reduction and prevention among injection and noninjection drug users. J. Acquir. Immune Defic. Syndr. 2010, 55(Suppl. 2):S84-S87.
17. Demchuk A.M., Morgenstern L.B., Krieger D.W., Chi T.L., Hu W., Wein T.H., Hardy R.J., Grotta J.C., Buchan A.M. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999, 30:34-39.
18. Derogatis, Melisaratos L.R. The brief symptom inventory: an introductory report. Psychol. Med. 1983, 13:595-605.
19. Des Jarlais D.C., Arasteh K., Perlis T., Hagan H., Abdul-Quader A., Heckathorn D.D., McKnight C., Bramson H., Nemeth C., Torian L.V., Friedman S.R. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City. AIDS 2007, 21:231-235.
20. Edelman E.J., Moore B.A., Caffrey S., Sikkema K.J., Jones E.S., Schottenfeld R.S., Fiellin D.A., Fiellin L.E. HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment. J. Addict. Med. 2013, 7:410-416.
21. Engstrom M., Shibusawa T., El-Bassel N., Gilbert L. Age and HIV sexual risk among women in methadone treatment. AIDS Behav. 2011, 15:103-113.
22. Fiellin D.A., Weiss L., Botsko M., Egan J.E., Altice F.L., Bazerman L.B., Chaudhry A., Cunningham C.O., Gourevitch M.N., Lum P.J., Sullivan L.E., Schottenfeld R.S., O'Connor P.G. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J. Acquir. Immune Defic. Syndr. 2011, 56(Suppl. 1):S33-S38. BHIVES Collaborative.
23. Fu T.C., Westergaard R.P., Lau B., Celentano D.D., Vlahov D., Mehta S.H., Kirk G.D. Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users. AIDS 2012, 26:2383-2391.
24. Gowing L., Farrell M.F., Bomemann R., Sullivan L.E., Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst. Rev. 2011, CD004145.
25. Kalichman S.C., Weinhardt L., DiFonzo K., Austin J., Luke W. Sensation seeking and alcohol use as markers of sexual transmission risk behavior in HIV-positive men. Ann. Behav. Med. 2002, 24:229-235.
26. Kapadia F., Latka M.H., Hudson S.M., Golub E.T., Campbell J.V., Bailey S., Frye V., Garfein R.S. Correlates of consistent condom use with main partners by partnership patterns among young adult male injection drug users from five US cities. Drug Alcohol Depend. 2007, 91(Suppl. 1):S56-S63. DUIT STudy Team.
27. Kapadia F., Latka M.H., Wu Y., Strathdee S.A., Mackesy-Amiti M.E., Hudson S.M., Thiede H., Garfein R.S. Longitudinal determinants of consistent condom use by partner type among young injection drug users: the role of personal and partner characteristics. AIDS Behav. 2011, 15:1309-1318.
28. Kidder D.P., Wolitski R.J., Pals S.L., Campsmith M.L. Housing status and HIV risk behaviors among homeless and housed persons with HIV. J. Acquir. Immune Defic. Syndr. 2008, 49:451-455.
29. Korthuis P.T., Tozzi M.J., Nandi V., Fiellin D.A., Weiss L., Egan J.E., Botsko M., Acosta A., Gourevitch M.N., Hersh D., Hsu J., Boverman J., Altice F.L. Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J. Acquir. Immune Defic. Syndr. 2011, 56(Suppl. 1):S39-S45. BHIVES Collabortive.
30. MacArthur G.J., Minozzi S., Martin N., Vickerman P., Deren S., Bruneau J., Degenhardt L., Hickman M. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ 2012, 345:e5945.
31. Marshall B.D., Wood E. Toward a comprehensive approach to HIV prevention for people who use drugs. J. Acquir. Immune Defic. Syndr. 2010, 55(Suppl. 1):S23-S26.
32. Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R.P., Myers B., Ambekar A., Strathdee S.A. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010, 375:1014-1028. 2009 Reference Group to the UN on HIV and Injecting Drug Use.
33. Mathers B.M., Degenhardt L., Phillips B., Wiessing L., Hickman M., Strathdee S.A., Wodak A., Panda S., Tyndall M., Toufik A., Mattick R.P. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008, 372:1733-1745. 2007 Reference Group to the UN on HIV and Injecting Drug Use.
34. Mattick R.P., Breen C., Kimber J., Davioli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, CD002207.
35. McHugh R.K., Weitzman M., Safren S.A., Murray H.W., Pollack M.H., Otto M.W. Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample. J. Psychoactive Drugs 2012, 44:237-242.
36. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., O'Brien C.P. New data from the addiction severity index: reliability and validity in three centers. J. Nerv. Ment. Dis. 1985, 173:412-423.
37. McPherson S., Barbosa-Leiker C., McDonell M., Howell D., Roll J. Longitudinal missing data strategies for substance use clinical trials using generalized estimating equations: an example with a buprenorphine trial. Hum. Psychopharmacol. 2013, 28:506-515.
38. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., DePhilippis D., Stolley P., Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J. Acquir. Immune Defic. Syndr. 1993, 6:1049-1056.
39. Mickey R.M., Greenland S. The impact of confounder selection criteria on effect estimation. Am. J. Epidemiol. 1989, 129:125-137.
40. Rubin D.B. Multiple imputation after 18+ years. J. Am. Stat. Assoc. 1996, 91:473-489.
41. SAS Institute Inc Longitudinal Data Analysis with Discrete and Continuous Responses Course Note 2009, SAS Institute Inc., Cary, NC.
42. Somlai A.M., Kelly J.A., McAuliffe T.L., Ksoblech K., Hackl K.L. Predictors of HIV sexual risk behaviors in a community sample of injection drug-using men and women. AIDS Behav. 2003, 7:383-393.
43. Strathdee S.A., Stockman J.K. Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions. Curr. HIV/AIDS Rep. 2010, 7:99-106.
44. Sullivan L.E., Fiellin D.A. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann. Intern. Med. 2008, 148:662-670.
45. Sullivan L.E., Moore B.A., Chawarski M.C., Pantalon M.V., Barry D., O'Connor P.G., Schottenfield R.S., Fiellin D.A. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J. Subst. Abuse Treat. 2008, 35:87-92.
46. Tetrault J.M., Kozal M.J., Chiarella J., Sullivan L.E., Dinh a.T., Fiellin D.A. Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. J. Addict. Med. 2013, 7:102-107.
47. Theall K.P., Clark R.A., Powell A., Smith H., Kissinger P. Alcohol consumption, ART usage and high-risk sex among women infected with HIV. AIDS Behav. 2007, 11:205-215.
48. Tyurina A., Krupitsky E., Cheng D.M., Coleman S.M., Walley A.Y., Bridden C., Gnatienko N., Zvartau E., Raj A., Samet J.H. Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers?. Drug Alcohol Depend. 2013, 132:74-80.
49. Vyavaharkar M., Moneyham L., Corwin S., Saunders R., Annang L., Tavakoli A. Relationships between stigma, social support, and depression in HIV-infected African American women living in the rural Southeastern United States. J. Assoc. Nurses AIDS Care 2010, 21:144-152.
50. Walley A.Y., Krupitsky E.M., Cheng D.M., Raj A., Edwards E.M., Bridden C., Egorova V.Y., Zvartau E.E., Woody G.E., Samet J.H. Implications of cannabis use and heavy alcohol use on HIV drug risk behaviors in Russian heroin users. AIDS Behav. 2008, 12:662-669.
51. Weiss L., Egan J.E., Botsko M., Netherland J., Fiellin D.A., Finkelstein R. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. J. Acquir. Immune Defic. Syndr. 2011, 56(Suppl. 1):S7-S13.
52. Westergaard R.P., Ambrose B.K., Mehta S.H., Kirk G.D. Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J. Int. AIDS Soc. 2012, 15:10.